Bioprocessing has always been a bit late in adopting the latest engineering techniques, e.g. computational fluid dynamics to bioreactor design ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

The double ring, spool-like structure of RAD52 protects replicating DNA in dividing cells. A study led by the University of ...

Research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in ...

Blocking Piezo2, a protein receptor that senses mechanical forces in tissues, may be a new way to slow IPF progression, per a ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Neurodegenerative disorders have increasing incidence with limited treatment options. Approaches to target neuroinflammation in various neurodegenerative disorders, such as Alzheimer’s disease (AD), ...

A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science (IBS), has uncovered a key cellular mechanism that affects the function of ...

Learn more about whether CRISPR Therapeutics AG or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Mapping an antibody’s epitope, where it binds a target, can now be done in three dimensions, which optimizes the selection of application-specific antibodies.

The Ontario Institute for Cancer Research (OICR) has announced its support for five Ontario research teams working to develop the next generation of medicines that kill tumours more effectively, cause ...